- AdventHealth
In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the iotaSOFT® Insertion System, the first FDA-authorized technology of its type. Approved for use in patients ages 12 years and older, iotaSOFT® is a robotic-assisted technology designed to aid surgeons in placing cochlear implant electrode arrays into a radiographically normal cochlea by controlling the speed of implant insertion. Studies have shown that reducing and controlling the insertion speed reduces trauma to the cochlea, improving surgical outcomes.
Neurotologist, AdventHealth Celebration
The Challenge — Slowing Insertion Speed to Prevent Residual Hearing Loss
An estimated 6.6 million Americans age 12 and older have severe to profound hearing loss in one or both ears. While hearing aids amplify external sounds, cochlear implants bypass damaged parts of the inner ear and directly stimulate the auditory nerve. They have improved hearing in patients with severe hearing loss for decades. However, most implant recipients experience additional loss of their natural hearing after surgery due to intracochlear trauma that can occur during manual insertion of the electrode array that is implanted in the cochlea.
“The spiral-shaped cochlea is very small, and the tissue is extremely delicate,” explains Dr. Seidman. “No matter how steady a surgeon’s hand, there is movement. Even slight variations can cause damage, negatively impacting the patient’s residual hearing, and we want to preserve as much of their residual hearing as possible. Furthermore, we know that maintaining a slow and consistent speed during insertion of the electrodes decreases force which is critical to minimizing pressure spike fluctuations that can also cause intracochlear structural trauma and hearing loss.”
Improving Cochlear Implant Precision and Outcomes
Robotics-assisted insertion has emerged as a way to reduce variability and standardize electrode insertions across individual surgeons and experience levels. A recent study found that compared with manual insertions, robotics-assisted insertions significantly decreased insertional intracochlear trauma.
Compatible with all three FDA-approved cochlear implant manufacturers, the iotaSOFT® system is comprised of a control console and a patient-mounted robotic drive unit that is the size of a thumb. The technology enables the surgeon to insert the electrode array at slower and more controlled speeds than the human hand — as low as 0.1mm/s. Dr. Seidman will offer this new approach to treat patients with debilitating hearing loss who are candidates for cochlear implants, including those with sensorineural (caused by damage to the inner ear or auditory nerve), noise-induced or genetic hearing loss.
“The beauty of the iotaSOFT® technology is that it allows for slower and steadier insertion,” Dr. Seidman says. “We believe it may improve patient outcomes by minimizing trauma and preserving residual hearing.”
Dr. Seidman and his team at AdventHealth Celebration plan to perform future studies evaluating the auditory outcomes of iotaSOFT® cochlear implant patients.
“As one of the busiest cochlear implant centers in the country, we are committed to providing our patients with the highest quality care and advanced technology, and we have a responsibility to contribute toward the growing field of knowledge on this new robotic approach,” shares Dr. Seidman. “We look forward to future research efforts and know that any improvement in hearing preservation we can achieve for our patients can make a huge difference in their quality of life.”
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...
AdventHealth Research Institute and NESTRE Health & Performance Announce Collaboration to Advance Neurocognitive Health and Performance Through Cognitive Training
With an aging population and increases in the prevalence of neurological conditions like Alzheimer’s disease and dementia, physicians and patients alike continue to seek new tools and approaches to...
AdventHealth Among First in U.S. to Offer IDP023-2-101 Clinical Trial for Patients with Progressive Multiple Sclerosis
The AdventHealth Neuroscience Institute is the first in Florida and one of the first in the country to begin recruiting patients with primary progressive or non-active secondary progressive multiple...